AngloGold Ashanti Limited vs Cassava Sciences Inc — how do they compare? AngloGold Ashanti Limited trades at $99.01 (market cap $49.19B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: AngloGold Ashanti Limited is far larger — about 1030.2× Cassava Sciences Inc's market cap, and AngloGold Ashanti Limited pays a 4.65% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| AU | FLNA | |
|---|---|---|
Market Cap | $49.19B | $47.75M |
Sector | Basic Materials | Health |
52-Week High | $128.26 | $4.64 |
52-Week Low | $52.15 | $0.87 |
Enterprise Value | $48.20B | -$34.93M |
Dividend Yield | 4.65% | — |
Signals from Pluang's Aura AI — not financial advice
AngloGold Ashanti (AU) surged 9.85% to $96.22 on strong gold price momentum and positive Q2 earnings. The stock trades near its 52-week high with bullish technical indicators and robust fundamentals including 26.64% net margins and 46.5% ROE. Recent quarterly results showed mixed performance with Q1 beating expectations while Q2 slightly missed, but strong free cash flow growth supports increased shareholder returns including dividends and a $2 billion buyback program.
Outlook remains positive with analyst consensus at $120.33 target (25% upside) and 64% buy ratings. Key catalysts include H2 production growth and gold price strength, while risks involve operational disruptions and commodity volatility. The company's improving balance sheet and cash generation support continued dividend payments and strategic initiatives.
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
Trailing returns across standard periods
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →